Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alz | Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurpris…